Nektar's Q2 2026: $1.02B Cash, Phase 3 ZENITH AD Underway, Runway to Q3 2028
NKTR has more than doubled off its 52-week low of $23.675.
Summary
Nektar Therapeutics reported Q2 2026 results with $1.02 billion in cash, initiated Phase 3 ZENITH AD trials, and extended cash runway into Q3 2028.
Key Events · Earnings and Guidance · NKTR
-
Q2 2026 Financial Results
Revenue of $10.1 million, net loss of $40.6 million ($1.23 per share), and cash/investments of $1,023.4 million as of June 30, 2026.
-
Cash Runway Extended
Cash runway extends into Q3 2028, past initial Phase 3 data readouts expected in mid-2028.
-
Phase 3 ZENITH AD Initiated
First two global registrational trials in atopic dermatitis initiated in July 2026; third trial to enroll patients with prior biologic/JAK inhibitor experience.
-
Alopecia Areata Phase 3 Planned
Single registrational Phase 3 study in alopecia areata planned to start in early 2027.
Analysis · NKTR · Life Sciences
A robust financial position underpins Nektar's Q2 2026 results, with over $1 billion in cash and investments extending the runway into Q3 2028. The company has initiated its Phase 3 ZENITH AD program in atopic dermatitis and plans a registrational Phase 3 study in alopecia areata in early 2027, targeting a first BLA submission for 2029. R&D spending increased significantly to support these trials, while G&A costs declined. Net loss per share improved to $1.23 from $2.95 year-over-year, reflecting the impact of the April 2026 equity offering that increased shares outstanding.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.5% of the 1629 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NKTR was trading at $76.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $23.68 to $109.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.